TORONTO, Feb. 5, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce that it will be hosting an investor webinar on Thursday, February 15, 2018 at 11:00 am Eastern time. The webinar will be led by Orefinders' CEO...Read More
TORONTO, Jan. 30, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to provide details on its newly acquired 100% owned Mann silver and cobalt mines in the Cobalt-Gowganda District of Ontario and its plans to create a pure play...Read More
TORONTO, Jan. 24, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is proud to announce that it has joined Young Mining Professionals ("YMP") and IAMGOLD Corporation ("IAMGOLD") to establish the YMP Scholarship Fund. The...Read More
TORONTO, Jan. 17, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) wishes to advise, pursuant to section 4.2(6) of Companion Policy 43-101CP, that it is not basing its production decision on a feasibility study of mineral reserves demonstratin...Read More
TORONTO, Jan. 15, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce positive results of the Company's Preliminary Economic Assessment (the "PEA") of the South Zone Open Pit (the "Project"), p...Read More
TORONTO, Jan. 5, 2018 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce that it has closed all of its Shining Tree area property acquisitions as described in November 30th, 2017's News Release. With the consolidation now...Read More
TORONTO, Dec. 29, 2017 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce it has received a subscription for a non-brokered flow through private placement of 1,500,000 units, at a price of $0.10 per unit, to raise proceeds of $...Read More
UPPSALA, Sweden, Dec. 12, 2017 /PRNewswire/ -- Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) in the US effective January 1, 2018, and previously announced in the Interim Report for the thir...Read More
TORONTO, Nov. 30, 2017 /CNW/- Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce that it has entered into agreements for a series of three acquisitions of contiguous properties from two individual landholders and from Premet Inc., a pr...Read More
UPPSALA, Sweden, Nov. 30, 2017 /PRNewswire/ -- On 31 October 2017,Orexo AB (publ) (the "Company") announced that the Company successfully had issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, and a floating inter...Read More
UPPSALA, Sweden, Nov. 22, 2017 /PRNewswire/ -- Orexo AB (publ.) (the "Company") today announces that the Company, in accordance with Orexo's press release on 31 October 2017, has completed the early total redemption of the existing bond loan (ISIN SE0005932159). The redemption...Read More
Uppsala, SWEDEN, November 20, 2017 /PRNewswire/ -- Orexo AB (publ.) today announce that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating treatment option for opioid dependence. Zubsolv, is a su...Read More
UPPSALA, Sweden, Oct.19, 2017 /PRNewswire/ -- Financial overview Q3 2017 Total net revenues SEK 166.2 million (181.9) Zubsolv (R) US net revenue SEK 121.1 million (142.4) EBIT SEK 40.9 million (43.0) EBITDA SEK 46.1 million (50.9) Earnings per share, before and after dilution, SEK 0.82/0.8...Read More
UPPSALA, Sweden, October 3, 2017 /PRNewswire/ -- Prior to the Annual General Meeting 2018, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information. The Nomination Committee, w...Read More
UPPSALA, Sweden, Oct. 2, 2017 /PRNewswire/ -- Orexo AB (publ.) today announced that Orexo has signed an asset purchase agreement with Gesynta Pharma AB - a recently formed research company located in Stockholm, Sweden. Among the founders are highly reputed executives from the biotech industry and...Read More
CAMBRIDGE, England and UPPSALA, Sweden, Sept. 15, 2017 /PRNewswire/ -- Mundipharma and Orexo AB (publ.) today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Zubsolv (buprenorphine and naloxone subli...Read More
UPPSALA, Sweden, Aug 2, 2017 /PRNewswire/ -- Orexo AB announced today changes to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence. Zubsolv's position has changed from excluded from rei...Read More
TORONTO, July 17, 2017 /CNW/ - Orefinders Resources Inc. ("Orefinders" or the "Company") (TSX.V: ORX) is pleased to announce that its shareholders have approved all resolutions brought before them at the Company's Annual General Meeting of Shareholders held on July 13, 2017, in Toronto, Onta...Read More
UPPSALA, Sweden, July 11, 2017 /PRNewswire/ -- Financial overview Q2 2017 Total net revenues SEK 159.1 million (188.2) Zubsolv (R) US net revenue SEK 124.1 million (112.8) EBIT SEK 9.8 million (12.1) EBITDA SEK 15.0 million (17.2) Earnings per share, before and after dilution, SEK 0.09/0.09 (0....Read More
UPPSALA, Sweden, June 30, 2017 The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of class C shares as announced on June 16, 2017. Today, the last trading day of the month, there are in total 35 104 585 shares - whereof 34,539,585 are ordinary shares...Read More